Drug Profile
RPh 201
Alternative Names: RPh-201Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Regenera Pharma
- Developer Hadassah Medical Organization; Regenera Pharma
- Class Antidementias; Eye disorder therapies; Herbal medicines
- Mechanism of Action Immunomodulators; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Optic nerve disorders
- No development reported Alzheimer's disease; Persistent vegetative state; Stroke
- Discontinued Chronic wounds
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Stroke in Israel
- 29 Nov 2022 No development reported - Phase-II for Alzheimer's disease (In the elderly, In adults) in Canada (SC) (NCT03462121)
- 29 Nov 2022 No development reported - Phase-III for Optic nerve disorders (In the elderly, In adults) in USA (SC) (NCT03547206)